Table 2b.
Allogeneic Patient Outcomes
| Home HCT (N=8) | Matched Controls (N=16) | P-value1 | |
|---|---|---|---|
| Mean Number of Clinic Visits (IQR) | 14.6 (9.5–17.8) | 47.4 (34.8–51.3) | <0.001 |
| Mean Days Hospitalized (IQR) | 17.8 (6.5–22) | 25.1 (16.8–37.3) | 0.28 |
| Mean Percent Time Hospitalized (IQR) | 21% (8%–24%) | 26% (16%–36%) | 0.52 |
| Median Days to Engraftment (IQR) | 16 (16–19) | 18.5 (16.5–24) | 0.22 |
| Median Days to Discharge (IQR) | 92.5 (72–93.5) | 86 (83–111.5) | 0.21 |
| Incidence of Febrile Neutropenia | 5 (62.5%) | 11 (68.8%) | 0.99 |
| Median Days of Febrile Neutropenia (IQR) | 13 (9–14) | 16 (11–18) | 0.29 |
| Incidence of Acute GVHD2 | 0.52 | ||
| Grade A | 1 (12.5%) | 4 (25%) | · |
| Grade B | 4 (50%) | 3 (18.8%) | · |
| Grade C | 0 (0%) | 1 (6.3%) | · |
| Grade D | 1 (12.5%) | 1 (6.3%) | · |
| Incidence of Chronic GVHD2 | 0.83 | ||
| Mild | 2 (25%) | 2 (12.5%) | · |
| Moderate | 1 (12.5%) | 3 (18.8%) | · |
| Severe | 0 (0%) | 0 (0%) | · |
| Clinically-Significant BSI3 peri-Transplant | 2 (25%) | 4 (25%) | 0.99 |
| LCBI4 Peri-Transplant | 2 (25%) | 3 (18.8%) | 0.99 |
| MBI-LCBI5 Peri-Transplant | 1 (12.5%) | 2 (12.5%) | 0.99 |
| Respiratory Infection Peri-Transplant | 3 (37.5%) | 3 (18.8%) | 0.36 |
| C. difficile Infection Peri-Transplant | 0 (0%) | 2 (12.5%) | 0.54 |
| csCMV6 peri-Transplant | 3 (37.5%) | 6 (37.5%) | 0.99 |
| Clinically-Signiiicqnt BSI3 1 Year Post-Transplant | 3 (37.5%) | 5 (31.3%) | 0.99 |
| LCBI4 1 Year Post-Transplant | 3 (37.5%) | 3 (18.8%) | 0.36 |
| MBI-LCBI5 1 Year Post-Transplant | 1 (12.5%) | 2 (12.5%) | 0.99 |
| Respiratory Infection 1 Year Post-Transplant | 4 (50%) | 4 (25%) | 0.36 |
| C. difficile Infection 1 Year Post-Transplant | 0 (0%) | 4 (25%) | 0.26 |
| csCMV6 1 Year Post-Transplant | 3 (37.5%) | 6 (37.5%) | 0.99 |
| Relapse 1 Year Post-Transplant | 2 (25%) | 7 (43.8%) | 0.66 |
| Mortality 1 Year Post-Transplant | 2 (25%) | 5 (31.3%) | 0.99 |
1
P-values obtained via t-test or Chi-square test.
2
GVHD: Graft-Versus-Host Disease.
3
BSI: Bloodstream Infection.
4
LCBI: Laboratory-Confirmed Bloodstream Infection.
5
MBI-LCBI: Mucosal Barrier Injury Laboratory-Confirmed Bloodstream Infection.
6
csCMV: Clinically-Significant CMV.